Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Traditionally, endotracheal intubation has been used as a treatment for patients with respiratory failure who require mechanical ventilation. Although intubation can be lifesaving, it is also associated with significant morbidity.1 Immunocompromised patients with acute hypoxemic respiratory failure are at particularly high risk; these patients often require high levels of ventilatory support (ie, positive end-expiratory pressure [PEEP] and fractions of inspired oxygen [Fio2]). Intubated patients usually require sedative medications, analgesic agents, or both and are at risk for many complications seen in the intensive care unit (ICU), such as ventilator-associated pneumonia, ICU-acquired weakness,2 venous thromboembolism,3 delirium, and cognitive dysfunction.4 As such, these patients typically have a high associated mortality, estimated at approximately 50%.5
Therefore, in modern ICU care, noninvasive ventilation is used frequently for the care of patients with acute respiratory failure. Specifically, this intervention can improve gas exchange and reduce the work of breathing without requiring an artificial airway. Consequently, patients treated with noninvasive ventilation may avoid some of the adverse consequences of invasive mechanical ventilation. The most compelling evidence for the benefits of noninvasive ventilation is from studies involving patients with exacerbations of chronic obstructive pulmonary disease6 and acute cardiogenic pulmonary edema.7 The benefits of noninvasive ventilation in hypoxemic immunocompromised patients are less compelling. Two small, randomized clinical trials demonstrated that use of noninvasive ventilation was associated with a substantial decrease in rates of endotracheal intubation, ICU complications, and mortality.5,8 However, these studies are old, and other studies that involved a heterogeneous population of patients with acute hypoxemic respiratory failure demonstrated high rates of treatment failure with noninvasive ventilation.9,10
Over the last 2 decades, the technology of noninvasive ventilation has changed substantially. The ventilators used in the 1990s delivered pressure through the ventilator circuit with room air as the source of fresh gas flow,6 with flow rates that were relatively low (ie, 10 to 35 L/min). These flow rates could be supplemented by oxygen delivered via a side port tubing connection. However, given that room air was the source of most of the fresh gas flow through the ventilator, the highest Fio2 that could be delivered was typically limited to 30% to 40%. Such ventilators were of limited utility in the care of patients requiring higher Fio2 levels. In addition, the ventilator interface was a rubber face mask that was often prone to air leakage when high pressures were needed.6 In contrast, modern noninvasive ventilation involves use of a ventilator with the fresh gas flow source coming directly from the medical oxygen and medical air sources. These connections allow for high pressure and flow and an Fio2 that can be titrated from 21% to 100% as needed. Furthermore, the interfaces now available for noninvasive ventilation administration include more compliant masks of various sizes; these tend to be much more comfortable, particularly for patients with acute hypoxemic respiratory failure, who often require higher levels of PEEP, higher driving pressures, or both.
Not only has noninvasive ventilation changed, but the case mix and care of critically ill patients with immunocompromise has also changed considerably over the last 20 years. Together, these issues have fueled controversy over the role of noninvasive ventilation for acute hypoxemic respiratory failure in this patient population. Therefore, Lemiale and colleagues11 tested the efficacy of noninvasive ventilation in immunocompromised patients in a multicenter randomized clinical trial, the results of which are published in this issue of JAMA. This study has many strengths. The investigators are an experienced group with a high level of expertise in the use of noninvasive ventilation for respiratory failure. The study was carefully designed, with excellent adherence to the protocol and 100% long-term follow-up. Even though it was impossible to blind the study groups, the end points of 28-day mortality and need for endotracheal intubation are objective and are subject to very low risk for bias affecting the outcome.
In contrast to studies from more than a decade prior, the investigators in the current trial were unable to demonstrate a mortality benefit, with 24.1% mortality in the group with early use of noninvasive ventilation (46 deaths among 191 patients) vs 27.3% mortality in the group receiving oxygen alone (50 deaths among 183 patients) (P = .47). Furthermore, intubation rates were not different between the groups (38.2% in the noninvasive ventilation group vs 44.8% in the oxygen alone group, P = .20).
However, before the use of noninvasive ventilation in immunocompromised patients is abandoned, these findings should be contextualized by advances in ICU care in the past 15 years, since publication of the seminal articles on this intervention in this type of patient population.5,8
First, overall mortality in the immunocompromised critically ill population has declined with advances in targeted chemotherapy, prophylactic use of antibiotics, and improved supportive care.12 In their study, Lemiale et al anticipated a higher baseline mortality of 35%, which limited their power to detect a mortality difference. Second, the patients enrolled in the earlier trials by Hilbert et al8 and Antonelli et al5 had greater degrees of tachypnea compared with patients in the current study (upper respiratory rate, 35-38/min vs 25/min), suggesting a greater severity of respiratory failure in the previous trials. However, unlike the earlier studies of noninvasive ventilation in acute hypoxemic respiratory failure,5,8 Lemiale et al did not report a severity of illness score (eg, Simplified Acute Physiology Score).13 Given the much higher respiratory rates and higher mortality in the earlier trials, it may be that the patients in this current trial had lower acuity of illness. Third, in the study by Lemiale et al, a greater proportion of patients in the oxygen alone group than in the noninvasive ventilation group received high-flow oxygen via nasal cannula. Given the recent findings of improved mortality with high-flow nasal cannula compared with noninvasive ventilation,14 perhaps the benefits from noninvasive ventilation were diluted with the use of this therapy. As the authors suggest, a comparison of high-flow oxygen and noninvasive ventilation for the management of acute hypoxemic respiratory failure in immunocompromised patients warrants further study. Therefore, all of these factors may have contributed to regression to the mean for the clinical outcomes in this negative trial.
The physiologic goals of noninvasive ventilation in the treatment of acute hypoxemic respiratory failure are to recruit lung with the proper use of PEEP and unload the respiratory muscles with the addition of pressure support ventilation. Physiologic studies examining use of noninvasive ventilation in acute lung injury have suggested that a PEEP of at least 10 cm H2O is required to significantly improve Pao2:Fio2 ratio with therapy.15 Furthermore, titration of PEEP and pressure support ventilation titration can be limited by the face mask leak and poor patient tolerance, even with modern ventilators and face mask interfaces, thus decreasing the efficacy of noninvasive ventilation delivered via face mask. With additional efforts to continue to reduce the percentage of critically ill patients who require invasive mechanical ventilation, alternative strategies for noninvasive ventilation that minimize face mask leak, improve oxygenation, and decrease work of breathing with alternative interfaces such as high-flow nasal cannula will need further investigation.
Corresponding Author: John P. Kress, MD, Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, 5841 S Maryland, MC 6026, Chicago, IL 60637 (email@example.com).
Published Online: October 7, 2015. doi:10.1001/jama.2015.12401.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Patel BK, Kress JP. The Changing Landscape of Noninvasive Ventilation in the Intensive Care Unit. JAMA. 2015;314(16):1697-1699. doi:10.1001/jama.2015.12401